Newsletters


Filter by volume

Agenus on Twitter

Agenus to Provide Corporate Update and Fourth Quarter & Full Year 2020 Financial Report investor.agenusbio.com/news-releases/…

$AGEN latest newsletter now available: Overcoming the Limitations of Current PD-1s Our PD-1 bal shows activity regardless of patients' #PDL1 status in R/M #cervicalcancer. Read about this potential differentiator & our work to identify better biomarkers: agenusbio.com/v4-i04_2021-ov…

S1E1 of Agenus Insights discussed #TIGIT the next validated #IO target in the immune revolution. @jbuell01 probed @ODayMD & @dhanschand on the key attributes of $AGEN TIGIT bispecific & what it adds to the current TIGIT landscape. See the replay for more: investor.agenusbio.com/events/event-d…

test Twitter Media - S1E1 of Agenus Insights discussed #TIGIT the next validated #IO target in the immune revolution. @jbuell01 probed @ODayMD & @dhanschand on the key attributes of $AGEN TIGIT bispecific & what it adds to the current TIGIT landscape. See the replay for more: https://t.co/dBDPPITayd https://t.co/ZZfRveFo32

$AGEN CTO Dr. Marc van Dijk to speak at #CARTCR Summit Europe on Wed Feb 17 @ 11am GMT on "Providing Mechanistic Rationale for Combination Therapies Through Functional Characterisation." Click to learn more & to register: cartcr-europe.com @CAR_TCell @Agentus_CellTX

The key to #biopharma development in 2021 will be advances in disease-fighting #technology. @jbuell01, President and COO of $AGEN, and other industry experts talk to @PharmaScrip about the progress they expect to see. Read about their vision here: scrip.pharmaintelligence.informa.com/SC143776

test Twitter Media - The key to #biopharma development in 2021 will be advances in disease-fighting #technology. @jbuell01, President and COO of $AGEN, and other industry experts talk to @PharmaScrip about the progress they expect to see. Read about their vision here: https://t.co/5xImWSRLVy https://t.co/DyjndaCYm2

TUNE IN today @ 1pm ET to "Optimally Targeting TIGIT" to hear @ODayMD & @dhanschand discuss the potential of #TIGIT as the next validated #IO target & the importance of Fc-enhancement for optimal performance. Learn more and register here: investor.agenusbio.com/news-releases/…

test Twitter Media - TUNE IN today @ 1pm ET to "Optimally Targeting TIGIT" to hear @ODayMD & @dhanschand discuss the potential of #TIGIT as the next validated #IO target & the importance of Fc-enhancement for optimal performance. Learn more and register here: https://t.co/ZB6RVs9YV3 https://t.co/kxtHkUR7WE

$AGEN is continuing to see responses that demonstrate the exciting potential of AGEN1181, our Fc-enhanced anti-CTLA-4. 2 new confirmed responses announced this week. See further updates in our corporate deck: bit.ly/2Njkmq8

$AGEN is excited to welcome Andy Hurley as Chief Commercial Officer! Andy brings 3 decades of experience as a strategic commercial leader in #biopharma. He comes to Agenus from @SyneosHealth where he served as Senior Vice President. Read more: investor.agenusbio.com/news-releases/…

test Twitter Media - $AGEN is excited to welcome Andy Hurley as Chief Commercial Officer! Andy brings 3 decades of experience as a strategic commercial leader in #biopharma. He comes to Agenus from @SyneosHealth where he served as Senior Vice President. Read more: https://t.co/1uPfkeSYHo https://t.co/gZ9D8OGSBF

$AGEN latest newsletter now available: A Powerful Team to Accomplish the Agenus Plan Agenus' #IO breakthroughs are driven by our innovative team. Read more about our new members’ vision for advancing & developing our strong pipeline of therapies: agenusbio.com/newsletters/v4…

Andy Hurley Named $AGEN Chief Commercial Officer bit.ly/3jAVPZZ

$AGEN announces Agenus Insights, a R&D miniseries that will offer key insights into the most impactful areas of research in #ImmunoOncology today. Join us for the inaugural episode "Optimally Targeting TIGIT" on Feb 11 at 1pm ET. Learn more & register: bit.ly/3jz5b8n

test Twitter Media - $AGEN announces Agenus Insights, a R&D miniseries that will offer key insights into the most impactful areas of research in #ImmunoOncology today. Join us for the inaugural episode "Optimally Targeting TIGIT" on Feb 11 at 1pm ET. Learn more & register: https://t.co/R3LW6iSzxn https://t.co/j0CbOaJtFZ

$AGEN Announces Agenus Insights - Virtual R&D Miniseries bit.ly/3jz5b8n

$AGEN announced 2 new responses today with its next-gen #CTLA4 AGEN1181 in #ovariancancer and MSS #colorectalcancer, indications that usually respond poorly to #immunotherapy, as @ODayMD points out. Read more: bit.ly/2Nb4fLy

test Twitter Media - $AGEN announced 2 new responses today with its next-gen #CTLA4 AGEN1181 in #ovariancancer and MSS #colorectalcancer, indications that usually respond poorly to #immunotherapy, as @ODayMD points out. Read more: https://t.co/9ZXwsaqX7K https://t.co/jX0HoaxSSC

$AGEN Announces New Responses for AGEN1181 bit.ly/2Nb4fLy

$AGEN announced promising preliminary results of its iNKT #celltherapy trial in patients w moderate to severe symptoms of #COVID19. 75% (3/4) patients extubated & released after treatment; 50% (2/4) extubated within 24 hours of treatment: bit.ly/2MRIIr9 @Agentus_CellTX

test Twitter Media - $AGEN announced promising preliminary results of its iNKT #celltherapy trial in patients w moderate to severe symptoms of #COVID19. 75% (3/4) patients extubated & released after treatment; 50% (2/4) extubated within 24 hours of treatment: https://t.co/6jlPJ1OiDF @Agentus_CellTX https://t.co/bBuQU0MIit

Could Cell Therapy Be The Answer To COVID-19? Click to learn more about @Agentus_CellTX iNKT cell therapy trial & the potential of these cells to fight #COVID19: cbsloc.al/2NXKoja

test Twitter Media - Could Cell Therapy Be The Answer To COVID-19? Click to learn more about @Agentus_CellTX iNKT cell therapy trial & the potential of these cells to fight #COVID19: https://t.co/mdxet3Fxsc https://t.co/tPwYn3sHJg

$AGEN Announces Positive Preliminary Results of iNKT Cell Therapy Trial in #COVID19 bit.ly/2MRIIr9

A recent @oncogenejournal article reports that $AGEN's PD-1 balstilimab has activity in recurrent/metastatic #cervicalcancer regardless of #PDL1 status & compares favorably to currently-approved therapies. Read more: go.nature.com/3auw1KH

For #cervicalcancerawarenessmonth, Agenus speaks w experts in the field of #gynecology about this deadly disease. Watch our latest newsletter to hear about the challenges faced by #cervicalcancer patients & the transformative potential of #immunotherapy bit.ly/2MddryC

Agenus Enters into Clinical Collaboration with Nelum for Zalifrelimab Combination bit.ly/3ojWKib